Rafferty Asset Management
CMPX icon

Rafferty Asset Management’s Compass Therapeutics CMPX Stock Holding History

Rafferty Asset Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$416K Sell
190,126
-5,741
-3% -$16.9K ﹤0.01% 938
2026
Q1 		$1.04M Buy
195,867
+44,124
+29% +$255K ﹤0.01% 756
2025
Q4 		$815K Buy
151,743
+80,784
+114% +$373K ﹤0.01% 829
2025
Q3 		$248K Buy
+70,959
New +$224K ﹤0.01% 1029

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Rafferty Asset Management's CMPX Position: Q2 2026 in Review

Rafferty Asset Management reduced its Compass Therapeutics (CMPX) stake by 2.9% in Q2 2026, selling an estimated $16.9K and leaving 190,126 shares worth $416K. The position accounts for ﹤0.01% of the portfolio, ranked #938.

Rafferty Asset Management first reported a position in CMPX in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.04M in Q1 2026. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Rafferty Asset Management held 190,126 shares of Compass Therapeutics worth $416K as of Q2 2026.
  • Rafferty Asset Management sold 5,741 Compass Therapeutics shares in Q2 2026, an estimated $16.9K.
  • Compass Therapeutics made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #938 holding.
  • Rafferty Asset Management first reported a position in Compass Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Rafferty Asset Management's Compass Therapeutics position peaked at $1.04M in Q1 2026.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.